A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials

Historically, phase II oncology trials assessed a treatment’s efficacy by examining its tumor response rate in a single-arm trial. Then, approximately 25 years ago, certain statistical and pharmacological considerations ignited a debate around whether randomized designs should be used instead. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Grayling, Michael J, Dimairo, Munyaradzi, Mander, Adrian P, Jaki, Thomas F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910171/
https://www.ncbi.nlm.nih.gov/pubmed/31218346
http://dx.doi.org/10.1093/jnci/djz126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910171/
https://www.ncbi.nlm.nih.gov/pubmed/31218346
http://dx.doi.org/10.1093/jnci/djz126

Ejemplares similares